Anti-AAV6 antibody and application thereof in AAV6 titer determination
By developing the Anti-AAV6 monoclonal antibody 3G8 and designing a double-antibody sandwich ELISA kit, the challenge of AAV6 vector titer determination was solved, achieving highly specific and accurate titer determination, and improving the quality control and safety of gene therapy drugs.
Patent Information
- Application Number
- CN202511316604.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-16
- Publication Date
- 2025-12-02
AI Technical Summary
The lack of highly specific AAV6 antibodies and reliable quantitative methods in existing technologies makes it difficult to determine the titer of AAV6 vectors, which affects the research and development and quality control of gene therapy drugs.
A highly specific anti-AAV6 monoclonal antibody, 3G8, was developed, and a double-antibody sandwich ELISA kit was designed based on this antibody for the specific capture and detection of AAV6 viral particles, enabling accurate titer determination.
It achieves highly specific identification and accurate quantification of AAV6 viral particles, reduces the risk of false positives, provides highly precise and repeatable titer determination results, and ensures the safety and efficacy of gene therapy drugs.